YD Bio Limited Ordinary Shares EBIT

YD Bio Limited Ordinary Shares (YDES) currently reports a EBIT of $-3M as of June 2025. That is below the Healthcare sector average of $22B. Use the charts on this page to explore YD Bio Limited Ordinary Shares's EBIT history and peer comparisons.

YD Bio Limited Ordinary Shares's EBIT of $-3M is lower than the Healthcare sector average of $22B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

YD Bio Limited Ordinary Shares reported $-3M in EBIT as of June 2025. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-3M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for YD Bio Limited Ordinary Shares, and consider following YDES for alerts when major investors trade the stock.

YD Bio Limited Ordinary Shares is classified in the Healthcare sector. On EBIT, it currently shows $-3M versus a sector average near $22B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing YDES with unrelated industries.